Daniel Alcalá-López

ORCID

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 4

Top Venues

Cancers

This page only lists publications with an associated author ORCID identifier.

Publications

Ana López González, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Cortes Salgado Alfonso, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena García, Petra Gener, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo, Javier Cortes, José Manuel Pérez-Garcia, Antonio Llombart-Cussac, Elena López-Miranda
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers 14 (23) (2022)
Ana López González, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Cortes Salgado Alfonso, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena García, Petra Gener, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo, Javier Cortes, José Manuel Pérez-Garcia, Antonio Llombart-Cussac, Elena López-Miranda
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers 14 (23) (2022)
Ana López González, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Cortes Salgado Alfonso, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena García, Petra Gener, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo, Javier Cortes, José Manuel Pérez-Garcia, Antonio Llombart-Cussac, Elena López-Miranda
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers 14 (23) (2022)
Ana López González, Sonia Del Barco Berrón, Isabel Grau, Maria Galan, Beatriz Castelo Fernández, Cortes Salgado Alfonso, Pedro Sánchez Rovira, Alejandro Martinez-Bueno, Xavier Gonzalez, Almudena García, Petra Gener, Leonardo Mina, Daniel Alcalá-López, Miguel Sampayo, Javier Cortes, José Manuel Pérez-Garcia, Antonio Llombart-Cussac, Elena López-Miranda
Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. Cancers 14 (23) (2022)

Daniel Alcalá-López.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Daniel Alcalá-López